---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129402"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:16:37.891075+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics prices $30M registered direct offering at $0.76/unit with warrants

## Summary
- Combined purchase price of $0.76 per share and warrant; $24M from institutional investors, $6M from Broadwood affiliate.
- Warrants exercisable at $0.91 for up to ~39.5M shares; expire 3 years from exercise date or 90 days post OpRegen milestone.
- Broadwood portion requires shareholder approval under NYSE American rules; closing contingent on satisfaction of conditions.
- Net proceeds to fund working capital, R&D, and capital expenditures; potential additional $36M if warrants exercised.
- H.C. Wainwright serves as exclusive placement agent with 7% cash fee and 5% warrant coverage at $0.95 exercise price.

## SEC filing metadata
- accession: 0000950170-24-129402
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024129402/0000950170-24-129402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024129402/lctx-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129402
- JSON: https://secwatch.observer/filing/0000950170-24-129402.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.